Nurix Therapeutics, Inc. (NRIX) Misses Q2 EPS by 8c

Nurix Therapeutics, Inc. (NASDAQ: NRIX) reported Q2 EPS of ($0.71), $0.08 worse than the analyst estimate of ($0.63). Revenue for the quarter came in at $12.09 million versus the consensus estimate of $22.11 million.

For earnings history and earnings-related data on Nurix Therapeutics, Inc. (NRIX) click here.

You May Also Be Interested In

• Trump on Iran: we're trying to work out a deal that's fair
• William Blair Upgrades Backblaze Inc (BLZE) to Market Perform
• Backblaze (BLZE) call put ratio 12.9 calls to 1 put with a focus on July 12.50 calls as share price up 40%